keyword
MENU ▼
Read by QxMD icon Read
search

Cytoreductive

keyword
https://www.readbyqxmd.com/read/28330549/-hyperthermic-intraperitoneal-chemotherapy-at-the-primary-gastrointestinal-cancer-operation
#1
Thea Helene Degett, Hans-Christian Pommergaard, Ismail Gögenur
Up to 20% of the patients who undergo radical surgery for colorectal cancer experience recurrence. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have shown to be effective treatment of peritoneal carcinomatosis. HIPEC administered at the primary operation in high-risk patients may also be effective in preventing peritoneal carcinomatosis and improve survival in patients with advanced gastrointestinal cancer.
March 20, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28326959/angiosarcoma-of-the-pelvis-in-a-13-year-old-girl
#2
Farah El-Sharkawy, Patricia Isabel Delgado, Antonello Podda, Holly Leigh Neville, Claudia Patricia Rojas
Angiosarcomas are highly aggressive malignancies of vascular origin and are very rarely found in children. We report a case of a 13-year-old girl with a history of abdominal pain and increased abdominal girth. Radiologic imaging showed significant ascites and large pelvic masses involving bilateral adnexa with abdominal spread. Microscopic examination of a biopsy revealed pleomorphic epithelioid and spindle cells with brisk mitotic activity, intracytoplasmic vacuoles, vascular channels, and large areas of hemorrhage and necrosis...
March 2017: Pediatric and Developmental Pathology
https://www.readbyqxmd.com/read/28325196/management-of-gastrointestinal-stromal-tumors
#3
REVIEW
Emily Z Keung, Chandrajit P Raut
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. The stomach is the most common site of origin. Management of GISTs changed after the introduction of molecularly targeted therapies. Although the only potentially curative treatment of resectable primary GISTs is surgery, recurrence is common. Patients with primary GISTs at intermediate or high risk of recurrence should receive imatinib postoperatively. Imatinib is also first-line therapy for advanced disease...
April 2017: Surgical Clinics of North America
https://www.readbyqxmd.com/read/28324285/preoperative-thrombocytosis-predicts-shortened-survival-in-patients-with-malignant-peritoneal-mesothelioma-undergoing-operative-cytoreduction-and-hyperthermic-intraperitoneal-chemotherapy
#4
Yue C Li, Tamara Khashab, Julia Terhune, Richard L Eckert, Nader Hanna, Allen Burke, H Richard Alexander
BACKGROUND: This study was designed to determine the clinical significance of preoperative thrombocytosis in patients with malignant peritoneal mesothelioma (MPM) undergoing operative cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). CRS and HIPEC have been associated with prolonged survival in patients with MPM and is the preferred treatment in select patients. However, patient selection criteria remain ill-defined for this operation that is also associated with significant morbidity and mortality...
March 21, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28321463/-when-is-surgical-resection-of-the-primary-tumor-indicated-in-metastatic-prostate-cancer-and-what-is-the-scientific-rationale
#5
J Noldus
Similar to other tumour entities, analyses of cancer databases giving hope that patients with advanced prostate cancer with osseous metastases benefit from cytoreductive surgery. Prospective clinical trials are in the process of proving this hypothesis. This review article focuses on molecular genetic pathways and clinical data.
March 20, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28321120/decision-analysis-of-allogeneic-hematopoietic-stem-cell-transplantation-for-patients-with-myelodysplastic-syndrome-stratified-according-to-the-revised-international-prognostic-scoring-system-ipss-r
#6
M G Della Porta, C H Jackson, E P Alessandrino, M Rossi, A Bacigalupo, M T van Lint, M Bernardi, B Allione, A Bosi, S Guidi, V Santini, L Malcovati, M Ubezio, C Milanesi, E Todisco, M T Voso, P Musto, F Onida, A P Iori, R Cerretti, G Grillo, A Molteni, P Pioltelli, L Borin, E Angelucci, E Oldani, S Sica, C Pascutto, V Ferretti, A Santoro, F Bonifazi, M Cazzola, A Rambaldi
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision making include the definition of optimal timing of the procedure and the benefit of cytoreduction before transplant in high risk patients. We carried out a decision analysis on 1728 MDS who received supportive care, transplantation or hypomethylating agents (HMAs). Risk assessment was based on the revised International Prognostic Scoring System (IPSS-R)...
March 21, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28317584/dealing-with-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancer-a-surgical-challenge
#7
REVIEW
Henri Azaïs, Juan Pablo Estevez, Périne Foucher, Yohan Kerbage, Serge Mordon, Pierre Collinet
Understanding biology and progression mechanisms of peritoneal metastases of epithelial ovarian cancer (EOC) is a cornerstone in the knowledge and the comprehensive management of the disease. Despite clinical remission after the association of complete cytoreductive surgery and platinum-based chemotherapy, peritoneal recurrence still occurs in 60% of patients. Eligible studies, published from 1980 to June 2016, were retrieved through ClinicalTrials.gov, MEDLINE, Cochrane databases and bibliography searches...
March 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28317007/the-role-of-neoadjuvant-chemotherapy-in-the-management-of-patients-with-advanced-stage-ovarian-cancer-survey-results-from-members-of-the-society-of-gynecologic-oncologists-a-5-year-follow-up
#8
Erica Huelsmann, Israel Zighelboim, Amina Ahmed, Summer Dewdney
•NACT use among SGO members for ovarian cancer is explored given recent trials.•Fewer SGO members feel they can't predict optimal cytoreduction pre-operatively.•Laparoscopy use has increased both for diagnosis and treatment of ovarian cancer.•Very high optimal cytoreduction rates are reported from SGO members.•Despite recent studies, SGO members don't regularly treat patients with NACT/ID.
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28316851/pure-primary-ovarian-squamous-cell-carcinoma-perforating-the-rectum
#9
Kazuya Mimura, Aiko Okada, Naotsugu Haraguchi, Kenjiro Sawada, Takuji Tomimatsu, Tadashi Kimura
Rectal perforation is uncommon in ovarian cancer, even in advanced stages. Pure primary ovarian squamous cell carcinoma is a very rare subtype of ovarian cancer and has not been reported to cause rectal perforation. A 50-year-old woman presented with rectal bleeding. Rectosigmoidoscopy suggested perforation of a pelvic tumor into the rectum. Abdominopelvic magnetic resonance imaging revealed a 9 cm heterogeneous mass in the pouch of Douglas. We performed complete cytoreduction, including an en-bloc resection of the tumor and rectosigmoid colon...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28315061/external-validation-of-the-simplified-preoperative-assessment-for-low-grade-mucinous-adenocarcinoma-of-the-appendix
#10
Vladimir Milovanov, Armando Sardi, Nail Aydin, Carol Nieroda, Michelle Sittig, Vadim Gushchin
BACKGROUND: MD Anderson Cancer Center developed a computed tomography (CT)-based preoperative assessment tool simplified preoperative assessment for appendix tumor (SPAAT) for predicting incomplete cytoreduction (IC) in low-grade mucinous adenocarcinoma (LGMA) of the appendix, based on preoperative CT scans. This study independently evaluates the tool's performance. METHODS: Seventy-six preoperative CT scans of LGMA patients were evaluated by two surgeons unfamiliar with the patients' medical history...
March 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28314973/-should-cytoreductive-nephrectomy-be-performed-in-patients-with-metastatic-renal-cell-carcinoma-and-what-is-the-scientific-rationale
#11
N Gilbert, A S Merseburger, M W Kramer
Between 15 and 20% of patients diagnosed with renal cell carcinoma suffer from metastatic disease by the time of diagnosis. In the immunotherapy era, the standard treatment was to perform cytoreductive nephrectomy (CN) followed by treatment with interferon α. This was based on two prospective randomized trials and their combined analysis. Since the introduction of targeted therapy, the use of CN came into question and the number of performed CN has declined. Two trials (CARMENA and SURTIME) evaluating the role of CN in the times of targeted therapy have either closed early or are recruiting slowly and will probably not be able to answer this question...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314968/-when-is-cytoreductive-nephrectomy-not-beneficial-for-patients-with-metastatic-renal-cell-carcinoma
#12
Martin Schostak
Primary tumor resection in patients with synchronous metastatic renal cell carcinoma and a good performance status corresponds to a guideline recommendation which, however, is based on weak data from the era of cytokine therapy. This article presents arguments that weigh heavily against cytoreductive nephrectomy. From a molecular genetic viewpoint, the intervention eliminates only the easiest adversary but cannot prevent cancer-related death. Therefore, benefits and risks must be carefully and critically considered...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28314967/-when-is-surgical-resection-of-the-primary-tumor-indicated-in-metastatic-urothelial-carcinoma-of-the-bladder-and-what-is-the-scientific-rationale
#13
J Ellinger, S Hauser, H Kübler, S C Müller
Cisplatin-based polychemotherapy is still the standard therapy for metastatic urothelial carcinoma, although disease progression is often noted at an early time point even in patients with response. In recent years, cytoreductive surgery has been gaining increasing interest in many tumor entities in the setting of metastatic disease to improve patients outcome, but urothelial carcinoma is not regarded as a candidate for such a multimodal therapy approach. However, several retrospective studies suggest a survival benefit of radical cystectomy and/or metastasectomy for well-selected patients with metastatic urothelial carcinoma...
March 17, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28303494/current-management-strategy-for-metastatic-renal-cell-carcinoma-and-future-directions
#14
REVIEW
Hussein Merza, Marijo Bilusic
PURPOSE OF REVIEW: Major strides have been made in the treatment of kidney cancer in the last several years with checkpoint immunotherapies and novel targeted agents. This manuscript will review current treatment strategies for metastatic renal cell carcinoma and will discuss future directions. RECENT FINDINGS: Most recently, several new drugs including nivolumab, cabozantinib, and a combination of lenvatinib and everolimus have demonstrated acceptable toxicity and significantly improved overall survival, but evidence-based guidelines for sequencing of the approved treatment options and treatment selection based on biomarkers are still missing...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28298076/chronic-kidney-disease-in-the-bcr-abl1-negative-myeloproliferative-neoplasm-a-single-center-retrospective-study
#15
Seung-Woo Baek, Ji Young Moon, Hyewon Ryu, Yoon-Seok Choi, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Samyoung Kim, Deog-Yeon Jo
Background/Aims: Renal complications related to BCR-ABL1-negative myeloproliferative neoplasms (MPNs) have not been examined fully in Asian populations. Methods: We analyzed estimated glomerular filtration rate (eGFR) and its changes with time retrospectively in patients with BCR-ABL1-negative MPN from 2005 to 2015. Results: The prevalence of chronic kidney disease (CKD) was 11% (6.6% having stage 3 and 4.4% having stage 4). In a linear regression analysis of eGFR versus time (years), overall, patients showed increased eGFR (mL/min/1...
March 17, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28291907/the-effects-of-hyperthermic-intraperitoneal-chemoperfusion-on-colonic-anastomosis-an-experimental-study-in-a-rat-model
#16
Afag Aghayeva, Cigdem Benlice, Ismail Ahmet Bilgin, Pinar Atukeren, Gulen Dogusoy, Figen Demir, Deniz Atasoy, Bilgi Baca
INTRODUCTION: Cytoreductive surgery (CRS) with subsequent hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising modality to treat and prevent peritoneal metastases. However, this treatment is associated with signficant morbidity and mortality. Whether or not CRS with HIPEC interferes with anastomotic healing has also been debated. This study was designed to investigate the effects of mitomycin C, cisplatin, oxaliplatin, and doxorubicin used in HIPEC treatment on colonic anastomosis healing in a rat model...
February 28, 2017: Tumori
https://www.readbyqxmd.com/read/28289659/single-center-experience-with-hyperthermic-intraperitoneal-chemotherapy
#17
Woo Ram Kim, Hyuk Hur, Byung Soh Min, Seung Hyuk Baik, Kang Young Lee, Nam Kyu Kim
PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate. We present our early experience with those procedures. METHODS: Data were retrospectively collected from all patients with peritoneal carcinomatosis (PC) and pseudomyxoma peritonei (PMP) treated using CRS and HIPEC at Yonsei Cancer Center between July 2014 and July 2015...
February 2017: Annals of Coloproctology
https://www.readbyqxmd.com/read/28289655/is-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-safe-and-effective-procedure-for-treating-patients-with-a-peritoneal-surface-malignancy
#18
EDITORIAL
https://www.readbyqxmd.com/read/28285846/a-comparative-analysis-of-prediction-models-for-complete-gross-resection-in-secondary-cytoreductive-surgery-for-ovarian-cancer
#19
Renee A Cowan, Ane Gerda Zahl Eriksson, Sara M Jaber, Qin Zhou, Alexia Iasonos, Oliver Zivanovic, Mario M Leitao, Nadeem R Abu-Rustum, Dennis S Chi, Ginger J Gardner
OBJECTIVE: We sought to examine compliance and outcomes using Memorial Sloan Kettering "(MSK) criteria" to predict complete gross resection (CGR) and compare them with the validated Tian and AGO models. METHODS: Patients who underwent SCS for recurrent platinum-sensitive ovarian cancer from 5/2001-6/2014 were identified. The AGO and Tian models were applied to the study population; appropriate statistical tests were used to determine ability to predict CGR. RESULTS: 214 SCS cases were identified...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285408/essential-thrombocythemia-presenting-as-acute-coronary-syndrome-case-reports-and-literature-review
#20
Nanqing Xiong, Wen Gao, Junjie Pan, Xinping Luo, Haiming Shi, Jian Li
For the patients with essential thrombocythemia (ET), systemic thrombosis presents as one of the most dangerous complications. It's been widely accepted that acute coronary syndrome (ACS) is a kind of thrombotic diseases. However, there are very few case reports about ET first presenting as ACS. For some patients diagnosed as ACS, but without markedly elevated platelet, underlying ET was missed. And there are some controversies in the principles and target of treatment in those patients. We reported three cases of ACS, in which the patients who did not have common risk factors for coronary artery diseases and presented only mild atherosclerotic stenosis during coronary angiography, one of which had recurrent coronary artery thrombosis...
March 11, 2017: Journal of Thrombosis and Thrombolysis
keyword
keyword
97237
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"